IGM Biosciences (IGMS)
(Delayed Data from NSDQ)
$15.99 USD
-0.17 (-1.05%)
Updated Sep 23, 2024 04:00 PM ET
After-Market: $16.00 +0.01 (0.06%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Balance Sheet
Fiscal Year End for IGM Biosciences, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 338 | 428 | 230 | 366 | 225 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 9 | 11 | 11 | 7 | 6 |
Total Current Assets | 348 | 438 | 241 | 373 | 231 |
Net Property & Equipment | 38 | 33 | 29 | 23 | 4 |
Investments & Advances | 0 | 0 | 0 | 0 | 12 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 2 | 2 | 1 | 1 | 0 |
Total Assets | 423 | 514 | 298 | 409 | 261 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 1 | 3 | 6 | 8 | 3 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 32 | 34 | 19 | 7 | 3 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 4 | 3 | 0 | 0 | 0 |
Total Current Liabilities | 42 | 45 | 28 | 17 | 9 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 143 | 146 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 220 | 226 | 53 | 27 | 21 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 1 | 0 | 0 | 0 | 0 |
Capital Surplus | 1,024 | 862 | 598 | 570 | 347 |
Retained Earnings | -821 | -575 | -354 | -189 | -107 |
Other Equity | 0 | -1 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 203 | 287 | 245 | 382 | 240 |
Total Liabilities & Shareholder's Equity | 423 | 514 | 298 | 409 | 261 |
Total Common Equity | 203 | 287 | 245 | 382 | 240 |
Shares Outstanding | 58.60 | 43.00 | 32.40 | 31.90 | 30.40 |
Book Value Per Share | 3.47 | 6.68 | 7.56 | 11.97 | 7.90 |
Fiscal Year End for IGM Biosciences, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 257 | 294 | 338 | 388 | 388 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 9 | 9 | 9 | 11 | 14 |
Total Current Assets | 266 | 303 | 348 | 398 | 402 |
Net Property & Equipment | 36 | 37 | 38 | 37 | 38 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 1 | 2 | 2 | 2 | 2 |
Total Assets | 337 | 376 | 423 | 474 | 481 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 3 | 4 | 1 | 4 | 5 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 26 | 24 | 32 | 28 | 28 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 2 | 4 | 4 | 5 | 5 |
Total Current Liabilities | 38 | 38 | 42 | 43 | 44 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 143 | 143 | 143 | 143 | 143 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 214 | 215 | 220 | 220 | 222 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 1 | 1 | 1 | 1 | 1 |
Capital Surplus | 1,041 | 1,032 | 1,024 | 1,014 | 957 |
Retained Earnings | -919 | -871 | -821 | -761 | -699 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 122 | 161 | 203 | 254 | 259 |
Total Liabilities & Shareholder's Equity | 337 | 376 | 423 | 474 | 481 |
Total Common Equity | 122 | 161 | 203 | 254 | 259 |
Shares Outstanding | 59.20 | 58.90 | 58.60 | 58.30 | 58.30 |
Book Value Per Share | 2.07 | 2.74 | 3.47 | 4.35 | 4.44 |